Bought a few of these as the news seems to be getting better and I am sure we have now seen the bottom

ains




Maelor Approved to Hold CE Marks


Maelor plc, the AIM quoted specialist healthcare products company, is pleased to
announce that its wholly-owned subsidiary, Maelor Pharmaceuticals Limited, has
been certified to hold its own CE Marks for medical devices associated with
sterile catheter irrigation solutions.


Maelor CEO Stephen Appelbee said:


'This approval is important because it will enable us to develop and launch our
own product brands using a Maelor CE Mark. This now allows us to accelerate the
launch programme of our range of sterile catheter irrigation solutions into
several worldwide markets under our own brand. Now that we have established our
certified status it will be a straightforward process to extend this to other
devices being developed from our pipeline.


It is also formal recognition that Maelor maintains the highest quality
standards in the development and manufacture of its products

"If we don't believe in freedom of expression for
people we despise, we don't believe in it at all."
-Noam Chomsky

Get read for the big bust out------
7. Maelor

Maelor is a specialist pharmaceutical and medical devices company in the critical care arena. A number of its products are 'must have' and represent 'life or death' for the patient. Its flagship critical care product, Volplex, is a blood plasma substitute that is used in operating theatres and hospital wards when a patient sustains heavy bleeding and requires fluid replacement. Since the sale of Volplex was brought back in-house following a strategic review by new management last June, Maelor's share of this market has doubled from 10 to 20 per cent. Competition is limited with only one other competitor, so there is still substantial room for growing market share.

However, the main reason for investing in Maelor is the transformational takeover of Acorus, which completed in May and funded by a 8m placing at 10p. Overnight, this has trebled the companys market capitalisation, strengthened and consolidated its niche position in the UK specialist critical care hospital market, and catapulted it into profitability. Acorus is a profitable and rapidly growing hospital specialist company with a highly synergistic portfolio of products also primarily focused in critical care.



Maelor says the acquisition of Acorus as transformational will create a strong, profitable business with positive cash flow. What the market seems to have failed to notice is that, as a division within Maelor, Acorus could have made an operating profit of 1.5m in 2006 against the 840,000 reported. In addition, with the acquisition of Acorus, which has much higher gross margins, margins for the enlarged group are forecast to rise further to 59 per cent from the 48 per cent reported in final results to March. The group is debt free and has an unused debt facility of 2m, which provides further funds for further bolt-on acquisitions. Trading since the period end is in line with expectations and, at 13.8p, its shares are on a modest multiple of 9.9 for the year to March 2009, when the benefits of the acquisition should really flow through. In May, there was cluster buying of 165,000-worth of shares by five directors at the placing price. The potential launch of Isoplex - a complementary product to Volplex - in 2008 is not factored into broker forecasts, either, which leaves the shares looking like a strong buy.




Source: Company REFs as at 21.06.07. *Source: Numis Securities. ** Classified under pharmaceuticals and biotechnology.

Nigel Milton owns shares in Celsis International, Corin, Deltex Medical, Maelor and Synergy Healthcare. During 2006, Nigel Miltons stock picks highlighted in the Best Small Stocks for 2006 feature in the Investors Chronicle (30 December 2005 issue) on average rose by 48.8 per cent.

In the true Adieh and BMW mannerism I post thusforth: MLR doing well this morning.

I SINCERELY TRUST THAT SOME OF YOU MAY HAVE BOUGHT MLR ON MY SUGGESTION.

I have a short term target price of 50p.

This share was trading at 2 pounds about 6 years back and on a lot less in fundamentals than it has today.

Good luck all.

Rise won't last...beware.

Well said Mr NEVERBEENER---NOW KINDLY PROVE YOU CONTENTION PLEASE WITH FACTS AND FIGURES.

The sp will inevitably fall back over the next few days...

My advice is to get into COH...great potential.

Its the weekend over the next few days stupid and the market is closed

Since you uneducatedly gobbed last the bid has moved up!

Nothing to sustain the rise...it will inevitably fall back.

Another tip...BKE UP 40%+ TODAY.

Rubbish MLR is undervalued--any idiot can see that.

BKE-- sorry I dont bother with no hopers.

BKE IS A RECOVERY STOCK...SKIES THE LIMIT WITH THIS ONE.

BKE BID UP AGAIN...DON'T MISS OUT GUY'S...

OH DEAR...A MASSIVE SELL GONE THROUGH ON HERE...DOES NOT BODE WELL.

wHAT A SILLY LITTLE PERSON YOU ARE. cANT YOU GET ANYTHING RIGHT.
I THINK IT WAS A BUY. I MAY BE WRONG--BUT IT DOES NOT MATTER WHATEVER IT WAS AS IT REINFORCED THE RISE TODAY AND SHARE CLOSED UP.

Please at least try to be , just a littlemature when posting.

YOU MUST TRY NOT TO GET TETCHY WHEN SOMEBODY DISAGREES WITH YOU

IT IS GOOD TO HAVE DIVERSITY

THE SP WILL GO DOWN NEXT WEEK UNLESS THERE IS NEWS

hahahahaha What a fool you are ever with mouth open and a closed brain.

It would appear over on the MLR thread on iii that the Investors Chronicle rates it a top buy. I reproduce the post here with full acknowledgment to both iii and the contributor. (I hold AMS and SYR).


Re: IC recommendation forwardloop
Yes - subscribers now get access to tips as and when they come out rather than having to wait until publicationday (Fri) MMs have marked up though.


What the Papers Say


INVESTORS CHRONICLE


Top Picks in Healthcare Sector:
*Deltex Medical (DEMG.L) - Synergy Healthcare (SYR.L) - BBI (BBI.L) - Celsis International (CEL.L) - Immunodiagnostic Systems (IDH.L) - Advanced Medical Solutions (AMS.L) - Maelor (MLR.L).


I know no more!

Just says top picks...where does it recommend a buy.

idiot! what the hell do you think a top pick is a shares mag means?

Calm down dear...buy means buy and sell means sell...now where does it say buy recomended.